Unknown

Dataset Information

0

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.


ABSTRACT: We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs).Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of eight cycles containing carboplatin were administered.All women (N=87) had good performance status and end-organ function. Incidences of carboplatin HSR before enrolment and on study were 17% and 21%, respectively. Most patients who developed carboplatin HSR had a deleterious BRCA1/2 mutation (93%) vs 50% in patients without HSR (P<0.0001). Multivariable analysis accounting for potential confounding variables including age, history of allergies, and cumulative prior carboplatin cycles confirmed deleterious BRCA1/2 mutation as an independent risk factor for carboplatin HSR (odds ratio 13.1 (95% confidence interval 2.6-65.4), P=0.0017). Mutation carriers had onset of carboplatin HSR at lower cumulative exposure (P=0.003). No significant difference in outcome was observed on our study between patients with and without a history of HSR.Deleterious BRCA1/2 mutation increased susceptibility and shortened time to carboplatin HSR, independently of other reported factors. These data suggest that at-risk women should be counselled regarding likelihood, symptoms, and potential earlier onset of carboplatin HSRs.

SUBMITTER: Moon DH 

PROVIDER: S-EPMC3749564 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Moon D H DH   Lee J-M JM   Noonan A M AM   Annunziata C M CM   Minasian L L   Houston N N   Hays J L JL   Kohn E C EC  

British journal of cancer 20130718 4


<h4>Background</h4>We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs).<h4>Methods</h4>Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of eight cycles containing carboplatin were administered.<h4>Results</h4>All women (N=87) had good performance status and end-organ function. Incidences of carboplatin HSR before enrolment and  ...[more]

Similar Datasets

| S-EPMC4106023 | biostudies-other
| S-EPMC6033627 | biostudies-literature
| S-EPMC7156285 | biostudies-literature
| S-EPMC7492508 | biostudies-literature
| 2067027 | ecrin-mdr-crc
| S-EPMC9880861 | biostudies-literature
| S-EPMC3406549 | biostudies-literature
| EGAS00000000037 | EGA
| S-EPMC7279169 | biostudies-literature
| S-EPMC7538657 | biostudies-literature